Sangamo selects PTC and Lilly as winning bidders in $163.55M asset auction

SANGAMO THERAPEUTICS, INC

PTC to buy Fabry program (ST-920) for $111M cash + up to $100M milestones ($80M on accelerated approval, $20M on full approval).
Lilly to buy capsid delivery, zinc finger, MINT platforms and prion program (ST-506) for $50M cash.
Tools/equipment sold to various bidders for $2.55M; total cash consideration ~$163.55M.
Sales subject to Bankruptcy Court approval; Lilly close expected ~Sept 4, 2026; PTC close after HSR review.
Company continues to market ST-503, hemophilia A program, cell therapy and T-Reg assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.